tirzepatide triple agonist Retatrutide: How the Compares to Dual and Triple Gut Peptide
Description
Dosing Information Usual Zepbound Dose for Weight Loss and OSA (Adult) Initial dose: 2.5 mg under the skin (subcutaneously) once a week
By activating both GLP-1 and GIP receptors, tirzepatide weight loss medications effectively reduce appetite, slow digestion for a longer feeling of fullness, enhance insulin sensitivity, and potentially increase calorie burning
Retatrutide (Phase 3 Clinical Trials, 2026) Retatrutide entered Phase 3 trials under the TRIUMPH program
Initially approved for T2D management, GLP-1 RAs have also demonstrated cardiovascular and renal benefits [57]
It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication
